Clinical Trial Update: First-in-human Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of C106 in Healthy Subjects [Phase 1]

View source ↗

Summary

Vicore Pharma AB's first-in-human Phase 1 study of C106 in healthy subjects assessed safety, tolerability, and pharmacokinetics; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Pulmonary Fibrosis
• Pulmonary Hypertension

Drugs mentioned

• C106

Snippet

Sponsor: Vicore Pharma AB | Conditions: Safety Issues, Tolerance | Phase 1 | Status: COMPLETED | Results posted: 2025-01-31